Cardiovascular predictors of death in patients with cirrhosis

Maurizio Cesari1, Anna Chiara Frigo2, Marta Tonon3

  • 1Clinica dell'Ipertensione, Department of Medicine, University of Padua, Padua, Italy.

Hepatology (Baltimore, Md.)
|September 14, 2017
PubMed

Insights

Cirrhotic cardiomyopathy impacts survival in liver cirrhosis patients. Cardiac function changes, like increased E/è ratio and left atrial enlargement, predict mortality, alongside MELD score, age, and BSA.

Area of Science:

  • Cardiology
  • Hepatology
  • Internal Medicine

Background:

  • Cirrhotic cardiomyopathy is a known complication in patients with cirrhosis.
  • Subclinical cardiac alterations may impact patient survival.
  • Early identification of cardiac risk factors is crucial for managing cirrhosis.

Purpose of the Study:

  • To investigate if subclinical cardiac morphologic and functional modifications influence survival in patients with cirrhosis.
  • To identify cardiac predictors of mortality in patients with cirrhosis.

Main Methods:

  • 115 patients with cirrhosis (without cardiovascular or pulmonary disease) underwent echocardiography.
  • Standard and tissue Doppler echocardiography assessed cardiac geometry, systolic/diastolic function, and hemodynamics.
  • Patients were followed for at least 6 years to record mortality.

Main Results:

  • 54 patients (47%) died during follow-up.
  • Univariate analysis linked age, BSA, MELD, blood pressure, heart rate, cardiac index, SVR index, and E/è ratio to mortality risk.
  • Multivariate analysis identified age, left atrial dimension, and BSA as predictors of death.
  • When MELD was included, MELD, age, and BSA were primary predictors.
  • Cardiovascular parameters independently predicting death included increased E/è, elevated heart rate, and reduced mean blood pressure.

Conclusions:

  • MELD, age, and BSA are primary predictors of mortality in cirrhosis patients.
  • Cardiac parameters such as left atrium enlargement, increased heart rate, elevated E/è ratio, and reduced mean blood pressure are independent predictors of death in cirrhosis.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
634
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
631
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
746
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
452
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
273